Regeneron Pharmaceuticals (REGN) Q1 2025 10-Q Quarterly Report
Regeneron Pharmaceuticals (REGN) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 29, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Regeneron Pharmaceuticals Q1 2025 10-Q Analysis
Risk Factors
- • New risk added: EYLEA HD FDA approval in August 2023 triggered dependence risk on EYLEA HD commercialization success
- • Updated risk: EYLEA U.S. net sales declined 39% YoY due to increased competition and market pressures, impacting revenue materially
- • Regulatory risk: Failure to comply with Medicaid Drug Rebate program could lead to penalties, sanctions, and additional reimbursement requirements
- • Operational risk: Manufacturing capacity insufficient to meet rising demand for EYLEA/EYLEA HD, dependence on collaborators and contract manufacturers increasing
- • Financial risk: Aggregate EYLEA HD and EYLEA U.S. sales represent 34% of total revenues in Q1 2025, concentration risk on these products significant
Regeneron Pharmaceuticals Q1 2025 Quarterly FinancialsXBRL
Revenue
$3.0B
▼ -3.7% YoY
Net Income
$809M
▲ +12.0% YoY
Net Margin
26.7%
▲ +374bp YoY
Source: XBRL data from Regeneron Pharmaceuticals Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Regeneron Pharmaceuticals Quarterly Reports
Get deeper insights on Regeneron Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.